Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for AgenT-797 in Virus-Induced Acute Respiratory Disease Syndrome. The expected timing is based on the latest available company guidance and may change.
03/21/24- Advance development to a much larger platform trial. Clinical data presented at ATS '24. 8/14/25- Advance into a Ph2 trial contingent to strategic collab and non-dilutive external funding. 11/14/25:- Launching randomized Ph2 severe pulmonary trial with FDA-validated endpoints. Early Ph2 data and broader pulmonary updates expected 2026. 02/03/26:- Human IPF tissue data show iNKT depletion, supporting iNKT cell restoration strategies for chronic fibrotic lung disease. 03/31/26:- ARDS Ph2 trial initiation H1 2026; readouts planned H2 2026; IPF Keystone data support expansion. 04/02/26:- Abstract accepted for ASGCT May 11-15, 2026 poster on cancer and ARDS. 05/12/26:- ASGCT Poster 3371 on May 14, 2026. Randomized Ph2 acute lung injury trial C-1300-02; preliminary data 2026. 05/14/26:- Randomized Ph2 ALI/ARDS trial C-1300-02 initiated in Ukraine; prelim data expected H2 2026. 05/28/26:- First patient dosed in Ph2 C-1300-02 ALI/ARDS trial; U.S. sites expanding; prelim data expected H2 2026. 08/06/26:- Day 28 observations encouraging in Ph2 C-1300-02. Additional data expected Early 2027. 08/13/26:- Initial Phase 2 C-1300-02 Day 28 data showed clinical recovery and no treatment-attributed major serious adverse events. Additional data are expected in Early 2027.
Verification
Confirm timing and program details against the company announcement or filing.